Bio-Convert Develops QR-02, a Potential Breakthrough in the Treatment of Oral Leukoplakia
BEVERLY HILLS, California, Feb. 03, 2025 (GLOBE NEWSWIRE) — Bio-Convert ApS («Bio-Convert”), a subsidiary of Nordicus Partners Corporation (OTCQB: NORD) (»Nordicus” or the «Company”), a financial consulting company specializing in supporting Nordic and U.S. life sciences companies in establishing themselves in the U.S. market, announces the groundbreaking development of QR-02, a unique and proprietary oral topical treatment designed to address oral leukoplakia with moderate to severe dysplasia, a potentially precancerous condition affecting millions worldwide.
Addressing a Critical Unmet Medical Need
Oral leukoplakia is characterized by white patches or plaques in the mouth, and when accompanied by dysplasia (abnormal cell growth), it becomes a marker of disease progression. Alarmingly, 10-30% of these patients may develop oral cancer, which has a five-year mortality rate exceeding 50%.
With 15.5 million oral leukoplakia patients in the U.S. and EU alone, there is an urgent need for an effective treatment to prevent disease progression. Given that 80% of leukoplakia lesions occur in the oral cavity, a therapy that remains in place for an extended period is critical for success.
QR-02: A Game-Changing Approach
Bio-Convert's QR-02 introduces a novel mucoadhesive oral formulation designed to adhere to the oral cavity for an extended period of 12-24 hours-a major advancement over traditional treatments, which last only 15-20 minutes due to the washout effect of saliva. This extended retention period significantly enhances drug efficacy and improves patient outcomes.
QR-02's active ingredient, imiquimod, is already FDA-approved for treating Actinic Keratosis, External Genital Warts, and Superficial Basal Cell Carcinoma (sBCC)-all superficial skin conditions. However, QR-02 is uniquely formulated for oral application, providing new hope for patients with oral leukoplakia and may also be beneficial in treating conditions that subsequently could occur in such patients.
AdvertisementPotential for a Transformative Impact
The goal of QR-02 is to treat and reduce dysplasia levels, potentially offering a curative solution for oral leukoplakia, an outcome that would mark a